U.S. Markets open in 6 hrs 4 mins
  • S&P Futures

    3,747.25
    -18.25 (-0.48%)
     
  • Dow Futures

    30,747.00
    -131.00 (-0.42%)
     
  • Nasdaq Futures

    12,380.00
    -75.00 (-0.60%)
     
  • Russell 2000 Futures

    2,134.80
    -9.70 (-0.45%)
     
  • Crude Oil

    64.57
    +0.74 (+1.16%)
     
  • Gold

    1,691.60
    -9.10 (-0.54%)
     
  • Silver

    25.25
    -0.21 (-0.81%)
     
  • EUR/USD

    1.1932
    -0.0047 (-0.3937%)
     
  • 10-Yr Bond

    1.5500
    0.0000 (0.00%)
     
  • Vix

    28.57
    +1.90 (+7.12%)
     
  • GBP/USD

    1.3854
    -0.0040 (-0.2895%)
     
  • USD/JPY

    108.3620
    +0.3860 (+0.3575%)
     
  • BTC-USD

    47,059.38
    -2,668.94 (-5.37%)
     
  • CMC Crypto 200

    940.50
    -46.71 (-4.73%)
     
  • FTSE 100

    6,591.64
    -59.24 (-0.89%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

3 Health Care Stocks Seeing Heightened Activity After Midterms

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / Healthcare stocks continued to gain momentum on Thursday morning following the build-up to US midterm elections held earlier this week. Sector trends in healthcare technology and new treatments for rare diseases have sparked more interest in the sector. Market participants see implementing self-service technology and giving accurate price estimates is key to improving the patient experience while ensuring a smooth revenue cycle.

With elections in mind, PwC surveyed 1,500 people, for instance, and found that 59% cited health care as a very important issue. "Healthcare providers stand to benefit from successful efforts to bolster individual and group markets, even as device and pharmaceutical manufacturers could find themselves more at risk for scrutiny as attempts to control rising healthcare costs focus increasingly on drug prices," analysts wrote in a post-election wrap-up.

With these trends in mind companies in focus today include Premier Health Group, Inc. (PHGRF) (CSE:PHGI), Sesen Bio, Inc. (SESN) and ReShape Lifesciences Inc. (RSLS)

In October, Premier Health Group, Inc. (PHGRF) (PHGI) announced that it has selected Reliq Health Technologies Inc. as its exclusive technology partner. Reliq will be providing Premier's subsidiary, HealthVue, primary care clinics with a HealthVue-branded telemedicine, remote monitoring & AI solution for its clinical staff and more than 100,000 active patients.

Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry. The company has recently seen market activity that is higher than average and could be attributed to the company's most recent announcements.

Premier Health Group, Inc. (PHGRF) (PHGI) announced this week that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019. With Premier's acquisition of HealthVue Medical Clinics in August, this could be the next phase of growth for the company.

Premier Health Group, Inc. (PHGRF) (PHGI) has already seen strong movement during the early morning session on Thursday and shares managed to briefly hit highs of $0.81 this week.

For More Information On Premier Health Group, Click Here

Sesen Bio, Inc. (SESN) saw a stronger premarket session on Thursday morning. Shares managed to hit highs of $1.90 before the opening bell. The company reported operating results for the third quarter ended September 30, 2018 and recent highlights from its development program for Vicinium® for patients with high-grade non-muscle invasive bladder cancer (NMIBC).

"2018 has been a year of focused execution for Sesen Bio, led by the advancement of the Phase 3 program for Vicinium for patients with NMIBC," said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. "NMIBC is a devastating disease and there remains just one recommendation for patients who do not respond or become refractory to today's standard-of-care treatment: complete bladder removal. Our goal is to help save this essential organ and provide a meaningful treatment option for patients with BCG-unresponsive NMIBC. Our Phase 3 registration clinical trial is well-designed and preliminary data reported earlier this year suggest that Vicinium is active and has a favorable safety profile, consistent with our Phase 2 experience. We look forward to assessing six-month data from the trial next month and twelve-month data in mid-2019. If the VISTA Trial is successful, we believe Vicinium could change the treatment outlook for patients with NMIBC, bringing us closer to achieving our mission of saving and renewing the lives of patients with cancer.

By the opening bell, shares of Sesen were trading over $1.80 per share.

For More Information On Sesen Bio, Click Here

ReShape Lifesciences Inc. (RSLS) announced a 1-40 reverse stock split on Wednesday that was approved by ReShape Lifesciences' stockholders at the company's special meeting of stockholders held on October 30, 2018. Following this news, the company announced Thursday morning that the ReShape Balloon System is now available at U.S. Department of Veterans Affairs medical facilities through the previously-announced ReShape Lifesciences partnership with Academy Medical, LLC.

Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and Department of Defense facilities. As of October 9, 2018, the ReShape Balloon has been added to Academy Medical's five-year sole source agreement with the U.S. Department of Veterans Affairs, which allows any VA surgeon in the U.S. to purchase the ReShape Balloon System from Academy Medical under a national contract.

"We are very pleased that surgeons at VA medical facilities now have the ability to treat veterans fighting obesity with the ReShape Balloon," said Dan Gladney, ReShape Lifesciences President and Chief Executive Officer.

Shares of ReShape traded widely during the first 15 minutes of the market being open between a low of $2.85 and a high of $3.55.

For More Information On ReShape, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com